{"id":4179,"date":"2026-11-10T09:00:00","date_gmt":"2026-11-10T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4179"},"modified":"2026-11-10T21:12:46","modified_gmt":"2026-11-11T01:12:46","slug":"second-pivotal-trial-supports-lumateperone-in-bipolar-mania","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4179","title":{"rendered":"Second Pivotal Trial Supports Lumateperone in Bipolar Mania"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_CAPLYTA_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4194\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_CAPLYTA_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_CAPLYTA_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_CAPLYTA_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_CAPLYTA_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Johnson &amp; Johnson Innovative Medicine<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 3 topline (Study 452)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small molecule (oral atypical antipsychotic)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Lumateperone (CAPLYTA)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>5-HT2A; D2 (proposed)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Bipolar I disorder, manic or mixed episodes<\/p>\n<h4>Summary<\/h4>\n<p>Johnson &amp; Johnson reported November 10 that its second randomized Phase 3 bipolar-mania study met primary and key secondary endpoints. The result extends a prior positive study but lumateperone remains unapproved for mania.<\/p>\n<p>Study 452 randomized adults with bipolar I manic or mixed episodes to once-daily lumateperone 42 mg or placebo for three weeks. The company reported a 3.7-point greater Young Mania Rating Scale reduction at week 3 (effect size \u22120.43, P&lt;0.0001); response of 43.9% versus 23.7%; and a Clinical Global Impression\u2013Severity difference of \u22120.41 (P=0.0003). Improvement was observed by day 3. Common treatment-related events exceeding placebo included dizziness, dry mouth and somnolence or sedation. A U.S. submission is planned.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> concordant pivotal trials strengthen the evidence for an additional approved bipolar I use and a single agent spanning depressive and manic phases. Randomization and symptom scales support efficacy over placebo. Counterargument: three-week benefit does not establish maintenance control, relapse prevention or comparative advantages over established antipsychotics.<\/p>\n<p><strong>Interpretation B:<\/strong> tolerability and metabolic profile could influence eventual choice, but the release lacks full adverse-event and weight\/metabolic tables for this study. Full published data, label review, longer follow-up, discontinuation and head-to-head effectiveness would refine positioning.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Lumateperone is an oral atypical antipsychotic approved in several U.S. psychiatric indications including bipolar depression. Its therapeutic mechanism is not fully known; serotonergic 5-HT2A antagonism and dopamine D2 partial agonism may contribute. Bipolar I mania requires rapid symptom control and safety assessment.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: company-reported randomized endpoint results and trial identifier NCT06462612.<\/li>\n<li>Missing: full baseline balance, completion rate, multiplicity hierarchy beyond key secondary, severe events and long-term outcomes.<\/li>\n<li>Mechanistic attribution to specific receptors is unproven.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A solid regulatory-stage efficacy signal for a new indication. Competitive and long-term clinical value remain separate questions.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive for the prespecified placebo comparison; uncertain for comparative use. Confidence in Facts: high for reported trial statistics. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &#038; Johnson reported November 10 that its second randomized Phase 3 bipolar-mania study met primary and key secondary endpoints. The result extends a prior positive study but lumateperone remains unapproved for mania.<\/p>\n","protected":false},"author":1,"featured_media":4194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[825,79,826],"class_list":["post-4179","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-bipolar-disorder","tag-johnson-johnson","tag-lumateperone"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4179"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4179\/revisions"}],"predecessor-version":[{"id":4200,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4179\/revisions\/4200"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4194"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}